[{"id":"9f5673ee-f7a4-40b1-ace8-59a97f2bd04f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01990196","created_at":"2021-01-18T09:04:40.027Z","updated_at":"2025-02-25T13:10:58.081Z","phase":"Phase 2","brief_title":"Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer","source_id_and_acronym":"NCT01990196","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" VIM • CDH2","pipe":" | ","alterations":" VIM expression","tags":["VIM • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • dasatinib • Xtandi (enzalutamide) • Firmagon (degarelix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/23/2014","start_date":" 09/23/2014","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-10-01"},{"id":"fedca6ff-e00b-46a6-ad22-bb62f954ee3a","acronym":"CTCO","url":"https://clinicaltrials.gov/study/NCT04696744","created_at":"2021-01-19T20:49:43.216Z","updated_at":"2024-07-02T16:35:17.264Z","phase":"","brief_title":"Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)","source_id_and_acronym":"NCT04696744 - CTCO","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" CDH2","pipe":"","alterations":" ","tags":["CDH2"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/23/2021","start_date":" 06/23/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-28"},{"id":"d6f98f26-2498-46cc-812f-de883aab657a","acronym":"PIONEER","url":"https://clinicaltrials.gov/study/NCT03306472","created_at":"2021-01-18T16:19:53.588Z","updated_at":"2024-07-02T16:35:21.649Z","phase":"Phase 2","brief_title":"A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer","source_id_and_acronym":"NCT03306472 - PIONEER","lead_sponsor":"Cambridge University Hospitals NHS Foundation Trust","biomarkers":" HER-2 • ER • CDH1 • CDH2","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1 • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • megestrol"],"overall_status":"Completed","enrollment":" Enrollment 198","initiation":"Initiation: 07/20/2017","start_date":" 07/20/2017","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-01-30"},{"id":"e6fa6f5f-f47f-4e45-ac2a-8106517e9c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT04021394","created_at":"2021-01-18T19:44:45.886Z","updated_at":"2024-07-02T16:35:51.538Z","phase":"","brief_title":"Influence of EMT on CTCs and Disease Progression in Prostate Cancer","source_id_and_acronym":"NCT04021394","lead_sponsor":"Lawson Health Research Institute","biomarkers":" CDH1 • EPCAM • CDH2 • ZEB1","pipe":" | ","alterations":" AR expression • CDH1 expression • EPCAM expression • ZEB1 expression","tags":["CDH1 • EPCAM • CDH2 • ZEB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • CDH1 expression • EPCAM expression • ZEB1 expression"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 04/27/2021","primary_completion_date":" 04/27/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-04-04"},{"id":"290b7fc0-2551-4b8e-8a40-119d81d3738c","acronym":"VitDURO","url":"https://clinicaltrials.gov/study/NCT04197089","created_at":"2021-01-18T20:27:15.791Z","updated_at":"2024-07-02T16:36:06.166Z","phase":"Phase 4","brief_title":"Biological Effect of Vitamin D in Patients With Urothelial Carcinoma","source_id_and_acronym":"NCT04197089 - VitDURO","lead_sponsor":"Germans Trias i Pujol Hospital","biomarkers":" FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5","pipe":"","alterations":" ","tags":["FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 11/22/2021","primary_completion_date":" 11/22/2021","study_txt":" Completion: 11/22/2021","study_completion_date":" 11/22/2021","last_update_posted":"2022-08-03"},{"id":"5c968a7c-8d14-474d-9a31-19f9508b0545","acronym":"","url":"https://clinicaltrials.gov/study/NCT03648879","created_at":"2021-03-25T15:53:02.111Z","updated_at":"2024-07-02T16:36:28.088Z","phase":"Phase 2","brief_title":"Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome","source_id_and_acronym":"NCT03648879","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA2 • CDH1 • CDH2 • CTNNA1","pipe":" | ","alterations":" PALB2 mutation • CDH1 mutation","tags":["BRCA2 • CDH1 • CDH2 • CTNNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • CDH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 02/11/2019","start_date":" 02/11/2019","primary_txt":" Primary completion: 04/20/2020","primary_completion_date":" 04/20/2020","study_txt":" Completion: 05/05/2020","study_completion_date":" 05/05/2020","last_update_posted":"2021-07-12"},{"id":"b58d1533-0218-4380-ae9a-a5ac5419f61d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02913859","created_at":"2022-06-07T00:00:48.059Z","updated_at":"2024-07-02T16:37:06.214Z","phase":"Phase 2","brief_title":"Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer","source_id_and_acronym":"NCT02913859","lead_sponsor":"University Hospital \"Sestre Milosrdnice\"","biomarkers":" CDH1 • VIM • CDH2","pipe":"","alterations":" ","tags":["CDH1 • VIM • CDH2"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2018-10-11"},{"id":"5218358d-3cd5-46b6-ae09-f982edd390ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02077777","created_at":"2021-01-18T09:34:37.178Z","updated_at":"2024-07-02T16:37:27.321Z","phase":"Phase 2","brief_title":"Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an \"in Vivo\" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.","source_id_and_acronym":"NCT02077777","lead_sponsor":"SOFAR S.p.A.","biomarkers":" MYC • CCND1 • CEBPA • KLF4 • CASP3 • TCF7L2 • CDH2 • CDKN1A • CDH23 • TCF4","pipe":" | ","alterations":" CCND1 expression","tags":["MYC • CCND1 • CEBPA • KLF4 • CASP3 • TCF7L2 • CDH2 • CDKN1A • CDH23 • TCF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2016-12-02"}]